uniQure to Build Therapy Production Plant in US to Leverage AAV Manufacturing Strength - - BioPharm International

ADVERTISEMENT

uniQure to Build Therapy Production Plant in US to Leverage AAV Manufacturing Strength



uniQure B.V. has announced it has commenced build-out of a 55,000 ft2  US manufacturing plant in Lexington, Mass., for the production of commercial grade Adeno Associated Virus (AAV)-based gene therapy products to complement its current EMA-approved site in Amsterdam, the Netherlands. The company expects the facility to be operational by early 2015.

The US site will expand the company's current production capacity. Once completed, it is expected to allow uniQure to capitalize on its modular manufacturing platform and leverage its process leadership in commercial grade AAV manufacturing, the company reports.

Source: uniQure
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines

Click here